Tu1526 – Prediction of High-Risk Individuals of Autoimmune Liver Disease by Health Check-Up: the Importance of Early Detection

2019 ◽  
Vol 156 (6) ◽  
pp. S-1353
Author(s):  
Yi Wang ◽  
Yanni Li ◽  
Ranko Gacesa ◽  
Xiaoyi Wang ◽  
Simin Zhou ◽  
...  
Keyword(s):  
Liver Disease ◽  
High Risk ◽  
Early Detection ◽  
Health Check ◽  
Autoimmune Liver Disease

scholarly journals Predicting Liver Disease Risk Using a Combination of Common Clinical Markers: A Screening Model from Routine Health Check-Up

2020 ◽  
Vol 2020 ◽  
pp. 1-11
Author(s):  
Yi Wang ◽  
Yanni Li ◽  
Xiaoyi Wang ◽  
Ranko Gacesa ◽  
Jie Zhang ◽  
...  
Keyword(s):  
Liver Disease ◽  
Early Detection ◽  
Predictive Power ◽  
Disease Screening ◽  
Health Check ◽  
Initial Presentation ◽  
Screening Tools ◽  
Clinical Markers ◽  
Liver Disorders ◽  
High Predictive Power

Background. Early detection is crucial for the prognosis of patients with autoimmune liver disease (AILD). Due to the relatively low incidence, developing screening tools for AILD remain a challenge. Aims. To analyze clinical characteristics of AILD patients at initial presentation and identify clinical markers, which could be useful for disease screening and early detection. Methods. We performed observational retrospective study and analyzed 581 AILD patients who were hospitalized in the gastroenterology department and 1000 healthy controls who were collected from health management center. Baseline characteristics at initial presentation were used to build regression models. The model was validated on an independent cohort of 56 patients with AILD and 100 patients with other liver disorders. Results. Asymptomatic AILD individuals identified by the health check-up are increased yearly (from 31.6% to 68.0%, p<0.001). The cirrhotic rates at an initial presentation are decreased in the past 18 years (from 52.6% to 20.0%, p<0.001). Eight indicators, which are common in the health check-up, are independent risk factors of AILD. Among them, abdominal lymph node enlargement (LN) positive is the most significant different (OR 8.85, 95% CI 2.73-28.69, p<0.001). The combination of these indicators shows high predictive power (AUC=0.98, sensitivity 89.0% and specificity 96.4%) for disease screening. Except two liver or cholangetic injury makers, the combination of AGE, GENDER, GLB, LN, concomitant extrahepatic autoimmune diseases, and familial history also shows a high predictive power for AILD in other liver disorders (AUC=0.91). Conclusion. Screening for AILD with described parameters can detect AILD in routine health check-up early, effectively and economically. Eight variables in routine health check-up are associated with AILD and the combination of them shows good ability of identifying high-risk individuals.

Severe course of Hepatitis E Virus infection in a patient with pre-existing autoimmune liver disease

2013 ◽  
Vol 51 (01) ◽  
Author(s):  
S Schlosser ◽  
J Pflaum ◽  
K Weigand ◽  
JJ Wenzel ◽  
W Jilg ◽  
...  
Keyword(s):  
Liver Disease ◽  
Virus Infection ◽  
Hepatitis E Virus ◽  
Hepatitis E ◽  
Autoimmune Liver Disease

Early Detection of Hepatocellular Carcinoma Requires a Combined Surveillance Protocol in High-Risk Individuals

Endoscopy ◽  
2006 ◽  
Vol 38 (11) ◽  
Author(s):  
A Qasim ◽  
T Tajjudin ◽  
B Zaman ◽  
D Maguire ◽  
J Geoghegan ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
High Risk ◽  
Early Detection ◽  
Surveillance Protocol

Have we learnt all from Improve-It? Part I. Core results and subanalyses on the effects of ezetimibe added to statin therapy related to age, gender and selected chronic diseases (kidney disease, diabetes mellitus and non- alcoholic fatty liver disease)

2020 ◽  
Vol 18 ◽  
Author(s):  
Zlatko Fras ◽  
Dimitri P. Mikhailidis
Keyword(s):  
Diabetes Mellitus ◽  
Liver Disease ◽  
High Risk ◽  
Kidney Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Risk Patients ◽  
Very High ◽  
Alcoholic Fatty Liver Disease

: IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) was a randomized clini- cal trial (18,144 patients) that evaluated the efficacy of the combination of ezetimibe with simvastatin vs simvastatin mono- therapy in patients with acute coronary syndrome (ACS) and moderately increased low-density lipoprotein cholesterol (LDL-C) levels (of up to 2.6-3.2 mmol/L; 100-120 mg/dL). After 7 years of follow-up, combination therapy resulted in an additional LDL-C decrease [1.8 mmol/L, or 70 mg/dL, within the simvastatin (40 mg/day) monotherapy arm and 1.4 mmol/L, or 53 mg/dL for simvastatin (40 mg/day) + ezetimibe (10 mg/day)] and showed an incremental clinical benefit (composite of cardiovascular death, nonfatal myocardial infarction, unstable angina requiring rehospitalization, coronary re- vascularization (≥30 days after randomization), or nonfatal stroke; hazard ratio (HR) of 0.936, and 95% CI 0.887-0.996, p=0.016). Therefore, for very high cardiovascular risk patients “even lower is even better” regarding LDL-C, independently of the LDL-C reducing strategy. These findings confirm ezetimibe as an option to treat very-high-risk patients who cannot achieve LDL-C targets with statin monotherapy. Additional analyses of the IMPROVE-IT (both prespecified and post-hoc) include specific very-high-risk subgroups of patients (those with previous acute events and/or coronary revascularization, older than 75 years, as well as patients with diabetes mellitus, chronic kidney disease or non-alcoholic fatty liver disease). The data from IMPROVE-IT also provide reassurance regarding longer-term safety and efficacy of the intensification of li- pid-lowering therapy in very-high-risk patients resulting in very low LDL-C levels. We comment on the results of several (sub) analyses of IMPROVE-IT.

Sign in / Sign up

Export Citation Format

Share Document